“Blood and marrow transplant clinical trials network (BMT CTN): addressing unanswered questions.”, Biol Blood Marrow Transplant, vol. 13, no. 3, pp. 257-62; discussion 255-6, 2007.
, “Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.”, Biol Blood Marrow Transplant, vol. 11, no. 8, pp. 571-5, 2005.
, “Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303.”, Biol Blood Marrow Transplant, vol. 18, no. 5, pp. 690-7, 2012.
, “Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl”, J Clin Oncol, vol. 30, no. 26, pp. 3194-201, 2012.
, “The Cord Blood Apgar: a novel scoring system to optimize selection of banked cord blood grafts for transplantation (CME).”, Transfusion, vol. 52, no. 2, pp. 272-83, 2012.
, “Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.”, Blood, vol. 114, no. 3, pp. 511-7, 2009.
, “One-unit versus two-unit cord-blood transplantation for hematologic cancers.”, N Engl J Med, vol. 371, no. 18, pp. 1685-94, 2014.
, “Optimizing donor selection for public cord blood banking: influence of maternal, infant, and collection characteristics on cord blood unit quality.”, Transfusion, vol. 54, no. 2, pp. 340-52, 2014.
, “Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C”, J Clin Oncol, vol. 31, no. 13, pp. 1662-8, 2013.
, “Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review.”, Biol Blood Marrow Transplant, vol. 9, no. 8, pp. 512-8, 2003.
, “Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.”, Blood, vol. 112, no. 12, pp. 4425-31, 2008.
, “Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants.”, Biol Blood Marrow Transplant, vol. 17, no. 9, pp. 1362-74, 2011.
, “Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT).”, Biol Blood Marrow Transplant, vol. 11, no. 2, pp. 149-60, 2005.
, “Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).”, Biol Blood Marrow Transplant, vol. 18, no. 8, pp. 1265-72, 2012.
, “Use of biological assignment in hematopoietic stem cell transplantation clinical trials.”, Clin Trials, vol. 5, no. 6, pp. 607-16, 2008.
,